Remdesivir Compulsory Licensing Is A Dead End For Europe
Possibility Had Been Mooted After US Struck Deal For Gilead Supply
In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.
